top of page
​

Selected publications

​

  1. Manel Zeghal, Kevin Matte, Angelica Venes, Shivani Patel, Geneviève Laroche, Sabina Sarvan, Monika Joshi, Jean-Christophe Rain, Jean-François Couture, Patrick M. Giguère. Development of a V5-tag-directed nanobody and its implementation as an intracellular biosensor of GPCR signalling. JBC In press. DOI:https://doi.org/10.1016/j.jbc.2023.105107 

  2. Zeghal M, Laroche G, Freitas JD, Wang R, Giguère PM. Profiling of basal and ligand-dependent GPCR activities by means of a polyvalent cell-based high-throughput platform. Nat Commun. 2023 Jul 5;14(1):3684. DOI: 10.1038/s41467-023-39132-x.

  3. Benlarbi M, Laroche G, Fink C, Fu K, Mulloy RP, Phan A, Ariana A, Stewart CM, Prévost J, Beaudoin-Bussières G, Daniel R, Bo Y, El Ferri O, Yockell-Lelièvre J, Stanford WL, Giguère PM, Mubareka S, Finzi A, Dekaban GA, Dikeakos JD, Côté M.Differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. iScience, 2022 Oct 10 DOI:https://doi.org/10.1016/j.isci.2022.105316

  4. Rossotti, M. A., van Faassen, H., Tran, A., Sheff, J., Duque, D., Sandhu, J., Hewitt, M., Wen, S., Bavananthasivam, R., Beitari, S., Matte, K., Laroche, G., Giguère, PM., Hussack, G., Langlois, M.-A., Durocher, Y.,y Tanha, J. Arsenal of Nanobodies for Broad-Spectrum Countermeasure against Current and Future SARS-CoV-2 Variants of Concern. Commun Biol. 2022 Sep 9;5(1):933

  5. Mohamud AO, Zeghal M, Patel S, Laroche G, Blgacim N, Giguère PM. *. Functional characterization of sodium-channel inhibitors activities at the delta-opioid receptor. ACS Omega. 2022 May 12;7(20):16939-16951.

  6. Thompson MJ, Domville JA, Edrington CH, Venes A, Giguère PM, Baenziger JE. Distinct functional roles for the M4 α-helix from each subunit in a hetero- pentameric ligand-gated ion channel. J Biol Chem. 2022 Jul;298(7):102104.

  7. Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Brown EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John C, Mahoney DJ, Ilkow CS, Giguère PM, Alain T, Côté M, Paludan SR, Olagnier D, Bell JC, Azad T, Diallo JS. Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen. Mol Ther. 2022 May 6;S1525-0016(22)00296-9

  8. Karunakaran G, Yang Y, Tremblay V, Ning Z, Martin J, Belaouad A, Figeys D, Brunzelle JS, Giguère PM, Stintzi A, Couture JF. Structural analysis of a cysteine desulfurase linked to Crohn's disease. FEBS Lett. 2022 Apr;596(7):898-909.

  9. Galipeau Y, Siragam V, Laroche G, Marion E, Greig M, McGuinty M, Booth R, Durocher Y, Cuperlovic-Culf M, Bennett SL, Crawley AM, Giguère PM, Cooper C and Langlois MA. Relative Ratios of Human Seasonal Coronavirus Antibodies Predict the Efficiency of Cross-Neutralization of SARS-CoV-2 Spike Binding to ACE2. EBioMedicine. 2021 Dec;74:103700.

  10. Rocheleau L, Laroche G, Fu K, Stewart CM, Mohamud AO, Côté M, Giguère PM*, Langlois MA*, Pelchat M*. Identification of a High-Frequency Intrahost SARS-CoV-2 Spike Variant with Enhanced Cytopathic and Fusogenic Effects. mBio. 2021 Jun 29;12(3) * Corresponding authors

  11. Stewart CM, Phan A, Bo Y, LeBlond ND, Smith TKT, Laroche G, Giguère PM, Fullerton MD, Pelchat M, Kobasa D, Côté M. Ebola virus triggers receptor tyrosine kinase-dependent signaling to promote the delivery of viral particles to entry-conducive intracellular compartments. PLos Pathog. 2021 Jan 29;17(1)

  12. Zeghal M, Laroche G, Giguère PM*. Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-TANGO assay. J Vis Exp. 2020 Mar 10;(157)

  13. Sun X, Laroche G, Wang X, Ågren H, Bowman GR, Giguère PM*, Tu Y*. Propagation of the allosteric modulation induced by sodium in the δ opioid receptor. Chemistry. 2017 Apr 3;23(19):4615-4624  * Corresponding authors

 
 
 
 
 
 
 

PUBLICATIONS

bottom of page